Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Brief Summary: This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC) in subjects with COPD. Subjects who meet the eligibility criteria at Screening will complete a 7 to 14 day Run-in period. At the end of the run-in period, approximately 710 eligible subjects will be equally randomized (to complete at least 568 evaluable subjects) to one of the 2 treatment groups for 12 weeks: 1. UMEC/VI 62.5/25 micrograms (mcg) administered as one inhalation once-daily in the morning via the Novel dry powder inhaler (NDPI) + placebo administered as one inhalation each morning and evening via single multidose powdered inhaler (ACCUHALER/DISKUS) or 2. FSC 250/50 mcg administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once-daily in the morning via NDPI. A safety Follow-up assessment will be conducted approximately 7 days after the end of the study treatment (Early Withdrawal, if applicable). The total duration of subject participation will be approximately 15 weeks.


Options:
A: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Umeclidinium/vilanterol Arm; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/vilanterol, Drug: Placebo | Arm Label: Fluticasone propionate/salmeterol Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol, Drug: Placebo | Intervention Type: DRUG; Name: Umeclidinium/vilanterol; Assigned to Arm(s): Umeclidinium/vilanterol Arm | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm, Umeclidinium/vilanterol Arm
C: Arm Label: Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg, Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg, Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg, Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo, Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo, Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg, Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg, Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg, Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg, Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg, Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg, Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg, Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo, Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg, Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg, Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo
D: Arm Label: Umeclidinium 62.5 mcg + placebo; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium, Drug: Umeclidinium matching placebo | Arm Label: Tiotropium 18mcg + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Tiotropium matching placebo | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Umeclidinium matching placebo; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18mcg + placebo | Intervention Type: DRUG; Name: Tiotropium matching placebo; Assigned to Arm(s): Tiotropium 18mcg + placebo

Answer: B